US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,245.97

-32.1173-2.51%

Number of Gainers:1

Number of Losers:5

Number of Flat:- -

PE:- -

High:1,284.58

Open:1,278.09

Low:1,245.85

Close:1,278.09

Loading ...

Teva Pharmaceuticals : UBS Cuts Target Price to $23 From $24

THOMSON REUTERS

Windtree Contracts Chinese Firm to Make Evofem's Contraceptive

Teva Releases Q2 2025 Aide Memoire

THOMSON REUTERS

Femasys Approves Director Elections and Share Increase

Femasys Inc. Conducted Annual Stockholders Meeting

Strategic Growth and Market Expansion: Femasys’s European Market Positioning and CE Mark Milestone

Femasys announces milestone with European approval of FemBloc

Femasys Announces Historic Milestone With European Approval of Fembloc®, the First Non-Surgical Permanent Birth Control

THOMSON REUTERS

Femasys Inc. Achieves European CE Mark Approval for FemBloc®, Pioneering Non-Surgical Permanent Birth Control Solution

Dare Bioscience Inc. Receives Nasdaq Panel Approval for Modified Compliance Plan; Faces Crucial July 31, 2025 Deadline to Avoid Delisting

BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

Veru Reports Positive Results From Phase 2B Quality and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

THOMSON REUTERS

Veru Inc - Enobosarm Shows 93% Greater Fat Loss, 100% Lean Mass Preservation

THOMSON REUTERS

Veru Inc - Enobosarm Monotherapy Shows Positive Safety Profile With No Gi Side Effects

THOMSON REUTERS

Veru Inc - Granted FDA Meeting to Discuss Phase 3 Clinical Program

THOMSON REUTERS

Veru Inc - Enobosarm 3Mg Reduces Weight Regain by 46% After Semaglutide Discontinuation

THOMSON REUTERS

Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch

Leader Capital Markets Remains a Buy on Teva (TEVA)

Femasys appoints Nicholas as CCO

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1245.9735,"timestamp":1750967999999,"preClose":1278.0908,"halted":0,"volume":18585171,"delay":0,"changeRate":-0.025129,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-32.11731,"latestTime":"06-26 16:00:00 EDT","open":1278.0912,"high":1284.5786,"low":1245.8544,"amount":237792597.35249,"amplitude":0.030299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751031000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.314685,"peRate":-15.032998,"turnoverRate":0.011248,"increases":1,"decrements":5,"flats":0,"marketCap":20314599648,"floatMarketCap":20176110698},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1284.5786,"amplitude":0.030299,"preClose":1278.0908,"low":1245.8544,"pbRate":"3.314685","latestPrice":1245.9735,"volume":18585171,"delay":0,"open":1278.0912,"prevYearClose":1682.2216,"prevWeekClose":1273.3816,"prevMonthClose":1265.8181,"prevQuarterClose":1184.288,"fiveDayClose":1281.3877,"twentyDayClose":1362.164,"sixtyDayClose":1184.288,"secType":"PLATE","market":"US","turnoverRate":0.011248,"peRate":-15.032998,"marketCap":20314599648,"floatMarketCap":20176110698,"timestamp":1750967999999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546790763","title":"Teva Pharmaceuticals : UBS Cuts Target Price to $23 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2546790763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546790763?lang=en_us&edition=fundamental","pubTime":"2025-06-27 16:44","pubTimestamp":1751013899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nAZN41TBDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4007","TEVA","BK4559","BK4566","BK4585","BK4596","BK4588","BK4584"],"gpt_icon":0},{"id":"2546519027","title":"Windtree Contracts Chinese Firm to Make Evofem's Contraceptive","url":"https://stock-news.laohu8.com/highlight/detail?id=2546519027","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546519027?lang=en_us&edition=fundamental","pubTime":"2025-06-27 04:57","pubTimestamp":1750971420,"startTime":"0","endTime":"0","summary":"Windtree Therapeutics said it has contracted with a pharmaceutical manufacturer in China to produce Evofem Biosciences's hormone-free contraceptive product Phexxi at a low cost.The biotechnology company, Evofem's sourcing partner for Phexxi since March, said Thursday that the contract should cut Phexxi's manufacturing costs by over 50% by the end of 2026.Windtree expects to start seeing some revenue from the arrangement next year.Early-stage manufacturing is set to begin later this year.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4139","BK4584","BK4007","WINT"],"gpt_icon":0},{"id":"2546594737","title":"Teva Releases Q2 2025 Aide Memoire","url":"https://stock-news.laohu8.com/highlight/detail?id=2546594737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546594737?lang=en_us&edition=fundamental","pubTime":"2025-06-27 04:30","pubTimestamp":1750969800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA4QTHCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4559","BK4557","BK4007","BK4566","BK4588","BK4596","BK4585","BK4584"],"gpt_icon":0},{"id":"2546263702","title":"Femasys Approves Director Elections and Share Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2546263702","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546263702?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:40","pubTimestamp":1750884054,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Femasys ( ($FEMY) ). On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximatel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-approves-director-elections-and-share-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-approves-director-elections-and-share-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4584","BK4539","FEMY"],"gpt_icon":0},{"id":"2546230502","title":"Femasys Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546230502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546230502?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:02","pubTimestamp":1750881748,"startTime":"0","endTime":"0","summary":"Femasys Inc. held its Annual Meeting of Stockholders on June 25, 2025. During the meeting, stockholders approved the election of Alistair Milnes and Edward Uzialko as Class I directors to the Board of Directors. An amendment to the Femasys Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for issuance by 3,000,000, was also approved. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securitie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDLwzQCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4539","BK4082"],"gpt_icon":0},{"id":"2546242391","title":"Strategic Growth and Market Expansion: Femasys’s European Market Positioning and CE Mark Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2546242391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546242391?lang=en_us&edition=fundamental","pubTime":"2025-06-25 23:45","pubTimestamp":1750866328,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Femasys (FEMY – Research Report) and keeping the price target at $12.00. Emily...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-growth-and-market-expansion-femasyss-european-market-positioning-and-ce-mark-milestone-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-growth-and-market-expansion-femasyss-european-market-positioning-and-ce-mark-milestone-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4109","BK4539","CE","FEMY","BK4082","BK4588","BK4584"],"gpt_icon":0},{"id":"2546243176","title":"Femasys announces milestone with European approval of FemBloc","url":"https://stock-news.laohu8.com/highlight/detail?id=2546243176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546243176?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:10","pubTimestamp":1750857017,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announces Conformite Europeene, CE, mark certification under European Union Medical Device Regulation of the Class III FemBloc blend...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-milestone-with-european-approval-of-fembloc-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-milestone-with-european-approval-of-fembloc-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4082","BK4539","FEMY"],"gpt_icon":0},{"id":"2546481702","title":"Femasys Announces Historic Milestone With European Approval of Fembloc®, the First Non-Surgical Permanent Birth Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2546481702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546481702?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:03","pubTimestamp":1750856597,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS02M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","FEMY","BK4082","BK4539"],"gpt_icon":0},{"id":"2546481672","title":"Femasys Inc. Achieves European CE Mark Approval for FemBloc®, Pioneering Non-Surgical Permanent Birth Control Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2546481672","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546481672?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:00","pubTimestamp":1750856428,"startTime":"0","endTime":"0","summary":"ATLANTA, June 25, 2025  -- Femasys Inc., a leading innovator in women's health, has achieved a significant milestone with the European approval of its FemBloc System, the first non-surgical permanent birth control solution. The system has received Conformité Européene  mark certification under the European Union Medical Device Regulation, marking the first regulatory approval of its kind globally. The FemBloc System, which includes a blended polymer component and a delivery system, can now be marketed across the European Economic Area. Femasys plans to roll out the product commercially in select European countries, beginning with Spain, while also pursuing further country approvals and continuing U.S. trials for FDA approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL8gY7QL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","LU2210149790.SGD","LU2095319765.USD","BK4539","BK4584","FEMY","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","BK4082","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2546217683","title":"Dare Bioscience Inc. Receives Nasdaq Panel Approval for Modified Compliance Plan; Faces Crucial July 31, 2025 Deadline to Avoid Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546217683","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546217683?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:01","pubTimestamp":1750852892,"startTime":"0","endTime":"0","summary":"Dare Bioscience Inc. Receives Nasdaq Panel Approval for Modified Compliance Plan; Faces Crucial July 31, 2025 Deadline to Avoid Delisting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL8xgwtp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","DARE","BK4007"],"gpt_icon":0},{"id":"2545287880","title":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2545287880","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545287880?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:36","pubTimestamp":1750768565,"startTime":"0","endTime":"0","summary":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study June 24 (Reuters) - Veru Inc VERU.O:VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","VERU","BK4007","BK4183"],"gpt_icon":0},{"id":"2545737282","title":"Veru Reports Positive Results From Phase 2B Quality and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545737282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545737282?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4183","BK4557","VERU","BK4007"],"gpt_icon":0},{"id":"2545282788","title":"Veru Inc - Enobosarm Shows 93% Greater Fat Loss, 100% Lean Mass Preservation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545282788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545282788?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","VERU","BK4007","BK4584","BK4557"],"gpt_icon":0},{"id":"2545282756","title":"Veru Inc - Enobosarm Monotherapy Shows Positive Safety Profile With No Gi Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2545282756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545282756?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4007","VERU","BK4183","BK4584"],"gpt_icon":0},{"id":"2545282733","title":"Veru Inc - Granted FDA Meeting to Discuss Phase 3 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2545282733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545282733?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4584","BK4557","BK4007","VERU"],"gpt_icon":0},{"id":"2545282227","title":"Veru Inc - Enobosarm 3Mg Reduces Weight Regain by 46% After Semaglutide Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545282227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545282227?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4584","VERU","BK4007","BK4183"],"gpt_icon":0},{"id":"2545414620","title":"Evofem Biosciences Inc. and Pharma 1 Drug Store Submit PHEXXI for Regulatory Approval in UAE, Targeting Q1 2026 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2545414620","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545414620?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:47","pubTimestamp":1750682845,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced that Pharma 1 Drug Store LLC, a private Emirati health care company, has filed an application with the United Arab Emirates  Ministry of Health and Prevention seeking approval to commercialize PHEXXI, Evofem's FDA-approved hormone-free contraceptive. This marks a significant step towards the international expansion of PHEXXI, with a targeted commercial launch in the UAE set for the first quarter of 2026. Following regulatory approval, Pharma 1 plans to place a launch quantity order for PHEXXI in July 2025. This collaboration highlights the growing demand for hormone-free contraception in the UAE and surrounding regions, and supports Evofem's strategy to diversify its revenue stream outside the U.S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL8d30mD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2545486890","title":"Leader Capital Markets Remains a Buy on Teva (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545486890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545486890?lang=en_us&edition=fundamental","pubTime":"2025-06-21 19:55","pubTimestamp":1750506908,"startTime":"0","endTime":"0","summary":"In a report released today, Sabina Levi from Leader Capital Markets maintained a Buy rating on Teva (TEVA – Research Report), with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leader-capital-markets-remains-a-buy-on-teva-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leader-capital-markets-remains-a-buy-on-teva-teva-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4007","BK4557","BK4584","TEVA","BK4585","BK4566","BK4588","BK4596"],"gpt_icon":0},{"id":"2544960740","title":"Femasys appoints Nicholas as CCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2544960740","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544960740?lang=en_us&edition=fundamental","pubTime":"2025-06-17 21:16","pubTimestamp":1750166187,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced the appointment of Kelley Nicholas as Chief Commercial Officer, CCO. Nicholas will be responsible for leading the executio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-appoints-nicholas-as-cco-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-appoints-nicholas-as-cco-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2249611893.SGD","LU0823414478.USD","LU0823414551.USD","BK4539","BK4082","BK4009","BK4584","FEMY","LU2294711713.HKD","LU2506951792.HKD","LU2357125470.USD","CCO"],"gpt_icon":0},{"id":"2544880960","title":"Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2544880960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544880960?lang=en_us&edition=fundamental","pubTime":"2025-06-17 21:00","pubTimestamp":1750165203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nTUA8GHWD8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","FEMY","BK4082","BK4584"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}